Intercell

<h2 id="history">History</h2>
It was founded in 1998 and focused on the research, development, and commercialization of vaccines and other biological products. Intercell AG's products were used to prevent and treat a variety of infectious diseases, including hepatitis B, Japanese encephalitis, and pneumonia. In 2012, Intercell AG merged with Vivalis SE, a French biotech company, to form <a href="/facts/Valneva/GKwSEqAG">Valneva</a>.<a class="footnote-ref" id="fnref:3" href="#fn:3">3</a> 
It has been listed on the <a href="/facts/Vienna_Stock_Exchange/faqlBc4d">Vienna Stock Exchange</a> since February 28, 2005. In 2008, Intercell signaled its intent to acquire <a href="/facts/Maryland/tVy9fC1n">Maryland</a>-based Iomai, a developer of needle-free vaccination technology.<a class="footnote-ref" id="fnref:4" href="#fn:4">4</a><a class="footnote-ref" id="fnref:5" href="#fn:5">5</a>
Intercell cooperates with <a href="/facts/Pharmaceutical_company/5mCITYys">pharmaceutical companies</a> like <a href="/facts/Novartis/jDregKez">Novartis</a>, <a href="/facts/Merck_%26_Co./8YD8dvwR">Merck</a> and <a href="/facts/Sanofi-Aventis/rLQc448b">Sanofi-Aventis</a> on vaccine production.
The most important projects of Intercell are:

<ul><li>Vaccine against <a href="/facts/Japanese_encephalitis/dXjMSu8z">Japanese encephalitis</a> (approved in Europe, America and Australia)<a class="footnote-ref" id="fnref:6" href="#fn:6">6</a><a class="footnote-ref" id="fnref:7" href="#fn:7">7</a><a class="footnote-ref" id="fnref:8" href="#fn:8">8</a></li></ul>
<ul><li>Therapeutic vaccine against <a href="/facts/Hepatitis_C/kwb7IIht">hepatitis C</a> (in clinical <a href="/facts/Clinical_trial/q8LMr832">phase II</a>)<a class="footnote-ref" id="fnref:9" href="#fn:9">9</a></li>
<li><a href="/facts/Antigen/9JlAernG">Antigen</a> identification program and <a href="/facts/Adjuvant/jnRqeBnG">adjuvant</a> technologies.</li>
<li>Vaccine Enhancement Patch to improve prevention against pandemic <a href="/facts/Influenza/nWuFzh6L">influenza</a> (in collaboration with <a href="/facts/United_States_Department_of_Health_and_Human_Services/eS90vYmd">U.S. Department of Health and Human Services</a>, in clinical phase II)</li></ul>

<h2 id="external-links">External links</h2>
<ul><li><a href="http://www.intercell.com/">Official website</a></li></ul>
<ul>
<li>Companies portal</li></ul>

<h2 id="references">References</h2>

<ol>
<li id="fn:1">Carroll, John (17 December 2012). "Troubled Intercell throws in the towel, signs off on merger deal with Vivalis". Fierce Biotech. Retrieved 27 January 2018. <a href="https://www.fiercebiotech.com/financials/troubled-intercell-throws-towel-signs-off-on-merger-deal-vivalis" target="_blank">https://www.fiercebiotech.com/financials/troubled-intercell-throws-towel-signs-off-on-merger-deal-vivalis</a> <a href="#fnref:1" class="footnote-back-ref">↩</a></li>
<li id="fn:2">"Research Institute of Molecular Pathology (IMP) - About the IMP > History". Research Institute of Molecular Pathology. Retrieved 2009-07-25. [dead link‍] <a href="http://www.imp.ac.at/about-the-imp/history/" target="_blank">http://www.imp.ac.at/about-the-imp/history/</a> <a href="#fnref:2" class="footnote-back-ref">↩</a></li>
<li id="fn:3">"The Dark Horse of the Vaccine Race May Be This French Biotech". Bloomberg.com. 2021-04-29. Retrieved 2023-01-09. <a href="https://www.bloomberg.com/news/articles/2021-04-29/a-french-biotech-says-inactivated-vaccines-are-the-way-to-fight-covid-variants" target="_blank">https://www.bloomberg.com/news/articles/2021-04-29/a-french-biotech-says-inactivated-vaccines-are-the-way-to-fight-covid-variants</a> <a href="#fnref:3" class="footnote-back-ref">↩</a></li>
<li id="fn:4">Fox, Maggie; Grenon, Andre (2008-05-12). "Austrian vaccine maker Intercell buys Iomai". Reuters. Archived from the original on 2011-06-20. Retrieved 2008-08-15. <a href="https://www.reuters.com/article/idUSN1233533220080512" target="_blank">https://www.reuters.com/article/idUSN1233533220080512</a> <a href="#fnref:4" class="footnote-back-ref">↩</a></li>
<li id="fn:5">Staff (1 June 2008), "Intercell to Acquire Iomai for $189M", Genetic Engineering & Biotechnology News, News: Inside Industry, vol. 28, no. 11, Mary Ann Liebert, Inc., p. 14, ISSN 1935-472X <a href="/wiki/ISSN_(identifier)" target="_blank">/wiki/ISSN_(identifier)</a> <a href="#fnref:5" class="footnote-back-ref">↩</a></li>
<li id="fn:6">"Intercell's Japanese Encephalitis Vaccine FDA approval". Medical News Today. 2009-03-31. Retrieved 2009-03-31. [dead link‍] <a href="http://www.intercell.com/main/forbeginners/news/not-in-menu/news-full/browse/1/back_to/news/article/intercell-announces-fda-approval-of-ixiaroR-a-vaccine-against-japanese-encephalitis-a-successf/" target="_blank">http://www.intercell.com/main/forbeginners/news/not-in-menu/news-full/browse/1/back_to/news/article/intercell-announces-fda-approval-of-ixiaroR-a-vaccine-against-japanese-encephalitis-a-successf/</a> <a href="#fnref:6" class="footnote-back-ref">↩</a></li>
<li id="fn:7">"Intercell's Japanese Encephalitis Vaccine EMEA approval for Europe". Intercell. 2009-04-02. Retrieved 2009-04-02. [dead link‍] <a href="http://www.intercell.com/main/forbeginners/news/not-in-menu/news-full/browse/1/back_to/news/article/intercell-announces-european-approval-of-new-vaccine-ixiaroR-to-prevent-japanese-encephalitis/" target="_blank">http://www.intercell.com/main/forbeginners/news/not-in-menu/news-full/browse/1/back_to/news/article/intercell-announces-european-approval-of-new-vaccine-ixiaroR-to-prevent-japanese-encephalitis/</a> <a href="#fnref:7" class="footnote-back-ref">↩</a></li>
<li id="fn:8">"Intercell's Japanese Encephalitis Vaccine Australian TGA approval". Intercell. 2009-01-23. Retrieved 2009-01-23. [dead link‍] <a href="http://www.intercell.com/main/forbeginners/news/not-in-menu/news-full/browse/2/back_to/news/article/australian-authorities-tga-first-to-grant-final-product-approval-for-intercells-vaccine-to-preven/" target="_blank">http://www.intercell.com/main/forbeginners/news/not-in-menu/news-full/browse/2/back_to/news/article/australian-authorities-tga-first-to-grant-final-product-approval-for-intercells-vaccine-to-preven/</a> <a href="#fnref:8" class="footnote-back-ref">↩</a></li>
<li id="fn:9">"Intercell Hepatitis C Vaccine Meets Primary Endpoints". FDA News. 2007-08-22. Retrieved 2008-08-15. <a href="http://www.fdanews.com/newsletter/article?articleId=97461&issueId=10614" target="_blank">http://www.fdanews.com/newsletter/article?articleId=97461&issueId=10614</a> <a href="#fnref:9" class="footnote-back-ref">↩</a></li>
</ol>

Intercell open-in-new

Intercell